Cargando…

Targeting transcription factors in cancer drug discovery

Cancer drug discovery is currently dominated by clinical trials or clinical research. Several potential drug candidates have been brought into the pipeline of drug discovery after showing very promising results at the pre-clinical level and are waiting to be tested in human clinical trials. Interest...

Descripción completa

Detalles Bibliográficos
Autor principal: Mitra, Partha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Open Exploration 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402400/
https://www.ncbi.nlm.nih.gov/pubmed/36046384
http://dx.doi.org/10.37349/etat.2020.00025
_version_ 1784773168018227200
author Mitra, Partha
author_facet Mitra, Partha
author_sort Mitra, Partha
collection PubMed
description Cancer drug discovery is currently dominated by clinical trials or clinical research. Several potential drug candidates have been brought into the pipeline of drug discovery after showing very promising results at the pre-clinical level and are waiting to be tested in human clinical trials. Interestingly, among the potential drug candidates, a few of them have targeted transcription factors highlighting the fundamental undruggable nature of these molecules. However, using advanced technologies, researchers were recently successful in partly unlocking this undruggable nature, which was considered as a ‘grey area’ in the early days of drug discovery, and as a result, several potential candidates have emerged recently. The purpose of the review is to highlight some of the recently reported studies of targeting transcription factors in cancer and their promising outcomes.
format Online
Article
Text
id pubmed-9402400
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Open Exploration
record_format MEDLINE/PubMed
spelling pubmed-94024002022-08-30 Targeting transcription factors in cancer drug discovery Mitra, Partha Explor Target Antitumor Ther Review Cancer drug discovery is currently dominated by clinical trials or clinical research. Several potential drug candidates have been brought into the pipeline of drug discovery after showing very promising results at the pre-clinical level and are waiting to be tested in human clinical trials. Interestingly, among the potential drug candidates, a few of them have targeted transcription factors highlighting the fundamental undruggable nature of these molecules. However, using advanced technologies, researchers were recently successful in partly unlocking this undruggable nature, which was considered as a ‘grey area’ in the early days of drug discovery, and as a result, several potential candidates have emerged recently. The purpose of the review is to highlight some of the recently reported studies of targeting transcription factors in cancer and their promising outcomes. Open Exploration 2020 2020-12-28 /pmc/articles/PMC9402400/ /pubmed/36046384 http://dx.doi.org/10.37349/etat.2020.00025 Text en © The Author(s) 2020. https://creativecommons.org/licenses/by/4.0/This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Mitra, Partha
Targeting transcription factors in cancer drug discovery
title Targeting transcription factors in cancer drug discovery
title_full Targeting transcription factors in cancer drug discovery
title_fullStr Targeting transcription factors in cancer drug discovery
title_full_unstemmed Targeting transcription factors in cancer drug discovery
title_short Targeting transcription factors in cancer drug discovery
title_sort targeting transcription factors in cancer drug discovery
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402400/
https://www.ncbi.nlm.nih.gov/pubmed/36046384
http://dx.doi.org/10.37349/etat.2020.00025
work_keys_str_mv AT mitrapartha targetingtranscriptionfactorsincancerdrugdiscovery